TG Therapeutics Inc. (NASDAQ: TGTX) announced that its phase 3 ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA